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Introduction
Improvements in immunosuppressive drugs, surgical
techniques and ancillary care have made transplantation a
routine and preferred therapy for treatment of end-stage
renal disease (ESRD) [1]. The incidence of ESRD is
increasing at a faster rate than the availability of kidney
donors [1], and the improvement in short-term graft sur-
vival rates has not been followed by substantial ameliora-
tion in long-term outcome [2]. Almost half of deceased
donor allografts will still be lost within 10 years after
transplantation, chronic allograft nephropathy (CAN)
being the most frequent cause of graft failure over a per-
iod of time [1–4]. In addition, transplant recipients show
a markedly increased risk for cardiovascular disease,
opportunistic infections and malignancy, which are the
complications of prolonged immunosuppression [5–7].
As a result, 50% of graft loss are caused by death of
patients with a functional graft [1,5–7]. Nowadays, the
discovery of potential markers of graft function outcome
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Summary
Several clinical and experimental models have underlined the role of the
CXCR3-binding chemokines in the immune-mediated kidney diseases. This
study aimed to investigate the predictive value of measuring pretransplant
CXCL9 levels for acute rejection (AR) onset and kidney transplantation out-
come. Pretransplantation serum levels of CXCL9 were tested retrospectively in
252 kidney graft recipients, whose stratification in two groups according to
CXCL9 levels (<272.1 pg/ml vs. >272.1 pg/ml) showed highly significant differ-
ences in 5-year survival rates (97.7% vs. 73.3%; P < 0.001). Multivariate analy-
sis demonstrated that among the analysed variables, CXCL9 [relative risk (RR)
11.708] and AR (RR 3.604) had the highest predictive power of graft loss.
Accordingly, patients with AR (254.4 ± 22.1; P < 0.05) and, even more, those
with anti-thymoglobulin (ATG)-treated AR also showed increased pretransplant
serum CXCL9 levels (319.3 ± 28.1, P < 0.001). Moreover, CXCL9 expression
and distribution were investigated in tissue specimens obtained from 10
patients affected by AR, and wide CXCL9 expression was detected not only in
infiltrating inflammatory cells but also in vascular and tubular structures. Mea-
surement of pretransplant serum CXCL9 levels might represent the tracking of
a clinically useful parameter to identify subjects at high risk of AR and graft
failure. These findings might be used for the individualization of immunosup-
pressive therapies.
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is a relevant clinical goal, and several clinical studies
aimed at evaluating possible predictive markers of graft
failure have been performed in order to identify patients
at high risk for graft loss [8–12].
Both clinical and experimental evidences indicate that
chemokines binding the CXC chemokine receptor 3
(CXCR3), may be particularly important for the immune
response to graft. Indeed, CXCR3 ligands playing a piv-
otal role in the initiation and amplification of host allore-
sponses and also altering vascular cell functions, promote
the development of acute rejection (AR), but also play a
role in the pathogenesis of chronic allograft dysfunction,
which finally leads to graft loss.
In previous studies, we have demonstrated that the
pretransplant serum level of the CXCR3 ligand CXCL10
is a clinically useful parameter for the identification of
subjects with a high risk of AR, chronic allograft
nephropathy, and graft failure [11,12]. Studies showing
the role of other CXCR3 binding chemokine have dem-
onstrated that the measurement of urinary levels of
CXCL9 is useful to predict AR onset [13]. Furthermore,
a recent study demonstrated that CXCL9 is an even
more powerful agent as compared with CXCL10 in
promoting CXCR3-dependent immune-mediated kidney
disease [14].
The aim of our study was to evaluate the prognostic
value of measuring the serum levels of CXCL9 before




Among patients with ESRD undergoing kidney transplan-
tation between 1991 and 2002 at the Florence and Bari
Transplant Centers, a final number of 252 caucasians sub-
jects (166 male and 86 female patients) entered the study.
Inclusion criteria were: (i) the availability of pretransplant
frozen serum aliquots, (ii) a complete clinical record for
at least 5 years since transplantation, (iii) a maintenance
immunosuppression therapy with calcineurin inhibitors.
Exclusion criteria were: (i) a Panel Reactive Antibody
(PRA) >20%, (ii) a living donor, (iii) an elderly
(‡60 years) deceased donor (iv) induction therapy with
any drug (basiliximab, rabbit anti-human thymocyte
globulins or ATG, OKT3, etc).
All patients were on dialysis at the time of transplant
and underwent measurements of main hematochemical
parameters every 6 months. An aliquot was obtained
from the serum specimen, which was used for final cyto-
toxic cross-match at the time of transplantation (within
6 months before the date of transplantation). Specimens
were kept frozen at )70 C until the time of assay.
End-stage renal disease (ESRD) resulted from glome-
rulopathies (34.1%), interstitial nephritis (19.7%), autoso-
mal dominant polycystic kidney disease (22.6%),
nephroangiosclerosis (12.7%), and others (11.1%). Infor-
mation on graft function, patient survival, and other clin-
ical data were retrospectively collected for each patient at
1, 3, 6 months and at 1, 2, 3, 4, 5 years. The mean fol-
low-up time after transplant, which included patients
who experienced graft failure, was 101.7 ± 46.3 months,
while the observed 5-year overall survival rate was 90.5%.
The maintenance immunosuppression consisted of a tri-
ple therapy including a calcineurin inhibitor (cyclosporine
in 93% and tacrolimus in 7%) with either azathioprine or
mycophenolate mofetil and steroids (prednisone).
All AR episodes were biopsy-proved, classified accord-
ing to Banff classification [15] and treated with steroids.
AR episodes showing vascular components at biopsy
(grade II or III) and failure to reverse after a course of
steroids were treated with ATG.
Renal biopsy specimens from a total number of 10 sub-
jects suffering from AR were used throughout the study.
As controls, normal kidney tissues were obtained from
five patients who underwent nephrectomy for the treat-
ment of primary localized renal tumors.
Gender- and age-matched adult healthy subjects
(n = 50) recruited from hospital staff and relatives were
used as controls. An informed consent, concerning the
future use of serum samples and clinical-pathologic data
for research purposes, was obtained from all the subjects
included in this study. This was in accordance with the
Regional Ethics Committee on human experimentation.
Serum assays
Serum CXCL9 was assayed by a quantitative sandwich
immunoassay using a commercially available kit, follow-
ing manufacturer’s instructions (R&D Systems, Minneap-
olis, MN, USA), with a mean minimum detectable dose
of 62.5 pg/ml and a maximum detectable dose of
4000 pg/ml. The intra- and interassay coefficients of vari-
ation were 2.1% and 6.3% respectively. Serum CXCL10
was assayed as previously described [10]. All serum sam-
ples that appeared above the maximum detectable levels
of the assays were diluted and assessed again and only the
final value was considered. Samples were assayed in dupli-
cate. Quality control pools at low, normal, and high con-
centrations for all parameters were present in each assay.
Immunohistochemistry
Immunohistochemical staining was performed as previ-
ously described [16]. For double label immunohistochem-
istry, the anti-CXCL9 (Peprotech, Rocky Hill, NJ, USA)
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pAb was applied first, and aminoethylcarbazole (AEC)
was used as peroxidase substrate. Sections were subse-
quently exposed to anti-CD68 (EBM11; Dako, Glostrup,
Denmark) and Vector SG (Vector Laboratories, Burlin-
game, CA, USA) was used as a chromogen. No counter-
stain was applied.
In situ hybridization
Cloning and sequencing of the CXCL9 probe and in situ
hybridization were performed as previously described
[16]. For combined in situ hybridization and immunohis-
tochemistry, after hybridization with the CXCL9 probe,
RNase digestion and appropriate washings, sections were
stained with anti-alpha-smooth muscle actin (a-SMA;
1A4; Sigma, Saint Louis, MO, USA) and then subjected
to autoradiography, as reported earlier [16].
Statistical analysis
Statistical analyses were performed using spss software
(SPSS, Inc., Evanston, IL, USA). Comparisons of variables
among different groups were performed by Student’s t-
test and Mann–Whitney U-test, as appropriate. Correla-
tion between two variables was ascertained by Pearson
and Spearman’s correlation test, as appropriate. Frequen-
cies were compared among groups by chi-squared test.
Kaplan–Meier estimates were used to generate overall
graft survival curves, censored for death with a function-
ing graft, and differences among groups were assessed by
log-rank test. Graft failure was defined as the need to
return to dialysis. To validate the effect of a variable on
graft survival, a Receiver operator characteristic (ROC)
curves analysis was performed to define an operational
cut-off level in order to better differentiate between
patient groups with and without graft loss with the high-
est specificity and sensitivity for the risk of graft loss. To
test the independent effects of different variables on
kidney allograft survival, Cox regression analysis was
used and partial correlation coefficients were computed.
A P-value <0.05 was considered statistically significant.
Results are expressed in the text as mean ± standard error
of the mean (SEM) unless otherwise stated.
Results
Pretransplant serum levels of CXCL9 in kidney graft
recipients and their relation to graft outcome
The mean serum levels of CXCL9 were significantly
higher in adult kidney graft recipients (n = 252) as com-
pared with healthy subjects (n = 50) (221.1 ± 9.4 vs.
37.3 ± 7.9 pg/ml respectively; P < 0.001).
No differences were observed in serum pretransplant
CXCL9 levels with regards to age, gender, year of trans-
plantation, original disease, transplant number, type or
duration of dialysis, PRA, or occurrence of delayed graft
function (data not shown).
To evaluate the possible relation between the pretrans-
plant variables and the kidney graft outcome, all patients
were assigned to two groups in relation to their5-year graft
outcome. The pretransplant clinical characteristics did not
differ significantly between the two groups (Table 1).
Patients with normally functioning grafts showed sig-
nificantly lower pretransplant serum CXCL9 levels than
those patients who experienced graft failure throughout a
5-year follow-up (205.6 ± 9.2 vs. 367.8 ± 31.8 pg/ml,
P < 0.001) (Fig. 1). This finding was confirmed when the
graft outcome was assessed at 12 (214.3 ± 9.4 vs. 356.2 ±
40.8 pg/ml, P < 0.001), 24 (212.1 ± 9.5 vs. 353.4 ±
33.4 pg/ml, P < 0.001), 36 (212.2 ± 9.5 vs. 356.0 ± 32.8
pg/ml, P < 0.001) and 48 months after transplantation
(210.8 ± 9.6 vs. 333.9 ± 28.1 pg/ml, P < 0.001).
To further investigate the effect of CXCL9 on graft sur-
vival, ROC curve cut-off was constructed in order to
define with the highest specificity and sensitivity the level
of CXCL9 allowing differentiation between patient with
and without graft loss. The cut-off value of pretransplant
CXCL9 for increased risk of graft loss was identified
at272.1 pg/ml (specificity 83.3%, sensitivity 75.4%, Area
Under the Curve 0.804, as shown in Fig. 2a; P < 0.001).
Table 1. Clinical characteristics of the
kidney transplant recipients and
distribution of the analysed variables
between patients with survived grafts
and patients undergoing graft failure.
Survived Failed P-value
No. patients 228 24
Recipient gender (M/F) 149/79 17/7 0.590
Age at transplantation (years) 46.2 ± 0.8 50.0 ± 2.6 0.106
Time on dialysis (months) 36.8 ± 2.3 27.2 ± 3.0 0.411
Type of dialysis (Hemodialysis vs.
Peritoneal dialysis)
200/28 18/6 0.083
Total mismatch (HLA-A. -B. -DR) 2.63 ± 0.06 2.79 ± 0.22 0.351
Donor gender (M/F) 138/90 12/12 0.318
Donor age (years) 42.2 ± 1.0 45.0 ± 2.3 0.557
Cold ischemia time (hours) 16.2 ± 0.3 17.9 ± 1.0 0.116
Transplant center (Bari versus Florence) 32/196 3/21 0.836
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Life-time analysis was performed after the assignment
of all patients to two groups according to the operational
cut-off of CXCL9. Recipients with pretransplant serum
CXCL9 levels <272.1 pg/ml (n = 173) showed signifi-
cantly higher 5-year rate of graft survival, as compared
with patients with serum CXCL9 levels >272.1 pg/ml
(n = 79) (97.7% vs. 73.3%; P < 0.001) (Fig. 2b). When
life-time analysis was performed to compare the rate of
survived grafts after 1, 2, 3 and 4 years, differences
between the two groups were significant at all time points
(data not shown).
Specificity of pretransplant CXCL9 for predicting graft
failure was further tested by comparing the CXCL9 serum
levels between surviving kidney recipients and patients
who died with functioning graft, but no influence of pre-
transplant serum CXCL9 on patient survival could be
observed. In fact, the CXCL9 levels between the two
groups were similar (219.4 ± 9.8 pg/ml and 230.1 ± 28.2
for surviving and dead recipients after 5 years respec-
tively; P = 0.882).
Combined measurement of both pretransplant serum
CXCL9 and CXCL10 levels in kidney graft recipients
and their relation to graft outcome
We have measured the pretransplant levels of CXCL10 in
our cohort of patients and we have related them to trans-
plant outcome. To this aim, we have assessed a CXCL10
cut-off value (133.2 pg/ml) to better differentiate between
patient groups with and without graft loss with the high-
est specificity and sensitivity for the risk of graft failure
(ROC AUC 0.753; Sensitivity 62.5%; Specificity 75.9%;
P < 0.001) and we have assigned the entire study cohort
to two groups according to their pretransplant serum
CXCL10 status: patients showing CXCL10 < 133.2
(n = 182) and patients showing CXCL10 < 133.2
Figure 1 Higher pretransplant serum CXCL9 levels in kidney recipi-
ents are associated with risk of graft failure. Pretransplant CXCL9
serum levels were significantly higher in patients who experienced
graft failure (n = 24) in comparison with patients with normally func-
tioning grafts (n = 228). (367.8 ± 31.8 vs. 205.6 ± 9.2 pg/ml; Mann–
Whitney U-test for unpaired data; *P < 0.001). Data are expressed as
median and 25th and 75th percentiles in boxes and 5th and 95th per-
centiles as whiskers while they are expressed as mean ± standard
error of the mean in the text.
Figure 2 Association of pretransplant serum CXCL9 levels with renal
allograft failure. (a) Prognostic value (ROC curve) of pretransplant
CXCL9 serum levels >272.1 pg/ml and the risk of allograft failure
[specificity 83.3%; sensitivity 75.4%; positive predictive values (PPV)
25.6%; negative predictive values (NPV) 97.7%; Area Under the
Curve (AUC) 0.804, Upper Limit 0.718, Lower Limit 0.890 for 95%
CI; P < 0.001] in a censored for death analysis of 252 patients. (b)
Recipients with serum CXCL9 levels below 272.1 pg/ml (n = 173,
black line) showed significantly higher 5 year-rate of graft survival in
comparison with patients with serum CXCL9 levels above this cut-off
(n = 79. dotted line) (97.7% vs. 73.3%; P < 0.001; Kaplan–Meier life-
time analysis and log-rank test). The outcome was ESRD requiring
RRT. Patients at risk were the number of cases in observation at each
time. The 5 years overall survival was 90.5%. In this analysis, death
with a functioning graft was not counted as graft failure.
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(n = 70). Life-time analysis has revealed 5-year graft
survival rates of 95.0% in the first group and of 78.6%
in the second group (Kaplan–Meier and log-rank
test; P < 0.001). No significant influence of pretrans-
plant serum CXCL10 on patients’ life survival was
observed.
Moreover, in order to evaluate a possible combined
role of both CXCL9 and CXCL10 chemokines onto graft
survival, patients have been assigned to four groups
according to their pretransplant serum chemokines status:
Group I (n = 148) patients showing both CXCL9 and
CXCL10 levels <ROC cut-off (272.1 and 133.2 pg/ml
respectively); Group II (n = 34) patients showing only
CXCL9 level >ROC cut-off; Group III (n = 29) showing
only CXCL10 level >ROC cut-off; Group IV (n = 41)
patients showing both CXCL9 and CXCL10 levels >ROC
cut-off. Life-time analysis revealed 5-year survival rates of
99.3% in Group I, 76.5% in Group II, 89.7% in Group
III and 70.7% in Group IV (Kaplan–Meier and log-rank
test; P < 0.001). In detail, recipients with both serum
CXCL9 and CXCL10 levels <ROC cut-off showed signifi-
cantly higher 5-year rate of graft survival in comparison
to patients with only CXCL9 (99.3% vs. 76.5%;
P < 0.001), or with only CXCL10 (99.3% vs. 89.7%;
P = 0.001), or with both the two chemokines >ROC cut-
off value (99.3% vs. 70.7%; P < 0.001). Noteworthy,
although no statistically significant differences have been
observed between Group II and Group III (76.5% vs.
89.7%; P = 0.21), between Group II and Group IV
(76.5% vs. 70.7%; P = 0.54), and between Group III and
Group IV (89.7% vs. 70.7%; P = 0.07), the percentages of
graft loss were consistently increased in recipients with
both serum CXCL9 and CXCL10 levels >ROC cut-off
value in comparison to patients with only CXCL9 or with
only CXCL10 > ROC cut-off value.
Predictive value of pretransplant serum CXCL9 levels
and other factors for graft failure
To estimate the relative risk for graft failure in patients
showing increased serum levels of CXCL9, Cox regression
analysis was performed using graft failure as dependent
variable, and pretransplant serum CXCL9, AR, recipient
age, total number of HLA mismatches, primary disease,
type of immunosuppression, cold ischemia time, donor
age, delayed graft function, type and time of dialysis, and
transplant center as covariates (Table 2). The only covari-
ates significantly affecting graft survival were the pretrans-
plant serum levels of CXCL9 and the occurrence of AR
(RR 11.708, CI 3.905–35.104, P < 0.001 and RR 3.604, CI
1.441–9.016, P < 0.01 respectively).
CXCL9 pretransplant serum levels predict recipient’s risk
of severe acute rejection
Acute rejection episodes occurred within the first year in
63 out of 252 recipients (25%), while from the second to
the fifth year the incidence of AR episodes increased by
5.2%, with a 5-year cumulative AR rate of 30.2%
(n = 76). Pretransplant serum levels of CXCL9 were com-
pared between patients who developed AR and patients
who did not, within the first year after transplantation.
As shown in Fig. 3a, rejectors showed significantly higher
median serum levels of pretransplant CXCL9 as compared
with non rejector recipients (268.8 ± 18.5 vs.
205.1 ± 10.6; P < 0.05). When the patients were assigned
Table 2. Cox regression analysis
showing the relative risk for allograft





Pretransplant serum CXCL9 levels <0.001 11.708 3.905 35.104
Acute rejection 0.006 3.604 1.441 9.016
Type of immunosuppression* 0.640 1.361 0.374 4.945
Recipient age at transplantation 0.098 1.042 0.993 1.094
Time on dialysis 0.274 0.988 0.968 1.009
Donor age 0.628 0.991 0.957 1.027
Cold ischemia time 0.111 1.074 0.984 1.172
Total mismatch (HLA-A -B -DR) 0.747 0.920 0.553 1.530
Original disease 0.238 1.214 0.880 1.674
Delayed graft function 0.697 1.223 0.444 3.365
Type of dialysis 0.227 1.874 0.677 5.182
Transplant center 0.213 0.363 0.074 1.786
*Cyclosporine-based versus Tacrolimus-based maintenance immunosuppression.
Hemodialysis versus Peritoneal Dialysis.
Bari versus Florence Transplant Center.
The parameters showing significant influences on graft survival are shown in bold characters.
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to two groups according to their pretransplant CXCL9
serum level, graft recipients with CXCL9 > 272.1 pg/ml
showed a significantly higher incidence of first-year AR
episodes than those with CXCL9 < 272.1 pg/ml (33.3%
vs. 21.5%, P < 0.05).
The same analysis was performed periodically during
the entire period of the study, which showed a 5-year AR
rate of 30.2% (n = 76), while the serum levels of pre-
transplant CXCL9 between rejectors and not rejectors
were also significantly different (259.9 ± 18.7 vs.
204.3 ± 10.5; P < 0.05).
Moreover, during the first year follow-up, the 14
patients who required anti-thymoglobulin (ATG) treat-
ment because of severe rejection, showing vascular com-
ponents at biopsy (grade II or III) and failure to reverse
after a course of steroids pulse, were characterized by
even higher pretransplant mean serum CXCL9 levels in
comparison with both patients who experienced AR epi-
sodes only treated with steroids (n = 49) and patient with
normally functioning grafts that did not experience AR
episodes (n = 189) during the 1-year follow-up
(319.3 ± 28.1 vs. 254.4 ± 22.1 vs. 205.1 ± 10.6 pg/ml,
P < 0.001) (Fig. 3b).
CXCL9 is highly expressed in kidney biopsies of subjects
with AR
To further investigate the role of CXCL9 in the onset of
AR, CXCL9 levels and distribution were assessed by in
situ hybridization and immunohistochemistry on kidney
tissue specimens from 10 subjects affected by acute allo-
graft rejection.
CXC chemokine ligand 9 (CXCL9) mRNA was absent
in normal kidney tissues (Fig. 4a), while it appeared to be
highly expressed in biopsy specimens from kidneys of
patients affected by AR (Fig. 4b and c), as assessed by in
situ hybridization. Sections hybridized with a sense
CXCL9 RNA probe showed virtually no signal (Fig. 4d).
Double immunostaining for CXCL9 and CD68 confirmed
that in AR, monocytes/macrophages were the main source
of this chemokine (Fig. 4e). Moreover, in kidneys from
patients with AR, positive cells were identifiable in vascu-
lar and tubular structures (Fig. 4f and g). Combined in
situ hybridization and immunohistochemistry for CXCL9
and a-SMA provided direct evidence that vascular
smooth muscle cells (SMC) (Fig. 4h), in addition to other
resident and infiltrating cells, were sources of CXCL9.
Discussion
Given the rapidly increasing number of patients with
ESRD, and the well-known problem of organ shortage,
successful renal transplantation with a high long-term allo-
graft survival rate has become essential. Despite the contin-
uous improvements in the immunosuppressive regimes,
the allograft AR remains one of the most relevant clinical
event in the post-transplant period. AR mainly occurs in
the early post-transplant period and, despite the fact that
(a)
(b)
Figure 3 Association of pretransplant serum CXCL9 levels with acute
rejection (AR). (a) Pretransplant serum mean levels of CXCL9 were sig-
nificantly higher in transplant recipients who experienced AR within
the first year after transplantation (n = 63) in comparison with
patients with normally functioning grafts that did not experience AR
episodes (n = 189) (268.8 ± 18.5 vs. 205.1 ± 10.6 pg/ml; Mann–
Whitney U-test for unpaired data; *P < 0.001). (b) Among graft recip-
ients, patients with normally functioning grafts that did not experi-
ence AR episodes (n = 189) exhibited lower pretransplant serum levels
of CXCL9 in comparison with both patients with early AR (n = 49)
and patients who experienced severe (antithymocyte globulin-treated)
AR episodes (n = 14) (205.1 ± 10.6 vs. 254.4 ± 22.1 vs.
319.3 ± 28.1 pg/ml, Kurskall–Wallis H-test for unpaired data:
P < 0.001; Mann–Whitney U-test for unpaired data: *P < 0.05;
**P < 0.001; * vs. **P < 0.05). Data are expressed as median and
25th and 75th percentiles in boxes and 5th and 95th percentiles as
whiskers while they are expressed as mean ± standard error of the
mean in the text.
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nowadays it causes graft loss only in a minority of cases, it
remains an important cause of comorbidity and hospital-
ization in kidney graft recipient population leading to the
development of chronic allograft dysfunction, which in
turn strongly affects the long-term outcome [17].
It has been a primary goal of transplant immunologists
to develop tests for assessing the pretransplant risk of
patients for immunologic rejection and graft failure. Vari-
ous risk factors, such as recipient age, number of HLA-A,
-B, and -DR mismatches, original disease, type of immu-
nosuppression, donor age and delayed graft function,
have all been proposed as means for differentiating
between patients with a good chance of long-term sur-
vival of a renal allograft and those with a poor chance.
In previous studies, we have evaluated the association
between elevated pretransplant serum levels of CXCL10
and the onset of AR, CAN and graft failure [11,12]. How-
ever, based on the recent finding demonstrating the lead-
ing role of CXCL9, another CXCR3 ligand, as mediator
of immune-mediated renal diseases [14], we aimed to
investigate the pretransplant serum content in CXCL9 in
a cohort of kidney graft recipients. In this study, pretrans-
plant levels of CXCL9 were measured in 252 patients
affected by ESRD who underwent kidney transplantation.
The predictive role of CXCL9 in relation to AR episodes
onset throughout a 1-year follow-up and kidney graft fail-
ure throughout a 5-year follow-up was evaluated. Patients
who experienced graft failure showed higher pretransplant
CXCL9 levels than patients with functioning graft. More-
over, in a multiple regression model including a number
of variables previously proposed as possible predictors of






Figure 4 CXCL9 expression and distri-
bution in kidney biopsy specimens from
patients affected by acute rejection (AR).
(a) Absence of CXCL9 mRNA expression
in a section of normal human kidney
(x100). (b–c) CXCL9 mRNA expression
(white grains in A, black grain in B at
the inflammatory infiltrating cells level
of a kidney specimen from a subject
affected by acute allograft rejection
(dark field in A, bright field in B, x100).
(d) Absence of signal in a section hybrid-
ized with a sense mRNA probe (x100).
(e) High CXCL9 protein expression at
level of infiltrating monocytes/macro-
phages, as demonstrated by double-lab-
el immunohistochemistry for CXCL9 (red
color) and CD68 (blue color) (arrows,
x400; selected area x800). (f) High
CXCL9 mRNA expression (black grains)
on tubular structures (x250). (g) High
CXCL9 mRNA expression (black grains)
lining the endothelial cells of a vessel
(x400). (h) Combined in situ hybridiza-
tion for CXCL9 mRNA (black grains) and
immunohistochemistry for a-smooth
muscle actin (red color), demonstrating
CXCL9 expression not only by vascular
smooth muscle cells (red cells), but also
by other resident and infiltrating cells
(x1000).
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CXCL9 greater than 272.1 pg/ml and the occurrence of
AR had a significant predictive power for allograft loss.
Accordingly, the pretransplant serum levels of CXCL9
were also able to predict the recipient’s risk for severe
AR, underlining the close correlation between the pre-
transplant immunologic status and the onset of post-
transplant immune-mediated events.
Furthermore, CXCL9 was found to be highly expressed
in kidney biopsy specimens obtained from patients
affected by acute allograft rejection, such expressions
related to infiltrating inflammatory cells, particularly mac-
rophages, the main sources of CXCL9.
More importantly, during AR, CXCL9 is expressed not
only by infiltrating mononuclear cells but also by vascular
and tubular structures. Indeed, the presence of CXCL9
mRNA on vascular smooth muscle cell, as demonstrated
by colocalization with a-SMA, suggest a possible link
between AR and development of chronic vascular dam-
age, leading to renal fibrosis and graft loss. This would be
in line with the notion that a-SMA is a specific marker of
activated fibroblast also known as myofibroblast [18],
which play a role in the pathogenesis of renal fibrosis
regardless of the initial cause [19,20]. Taken together,
these findings are suggestive of a role for CXCL9 not only
in pathogenesis of AR but also in the onset of chronic
allograft dysfunction and, finally, graft failure.
The chemokines CXCL10 and CXCL9 are members of
the C-X-C subfamily. They induce chemotaxis of stimu-
lated human T lymphocytes and are believed to be more
important in the Th1-type immune responses [21,22].
CXCL9 and CXCL10 are able to mediate pleiotropic bio-
logic functions [23–25], and are involved in transplant
tolerance through CXCR3 receptor interaction [26–28].
These chemokines are potent chemoattractants for acti-
vated lymphocytes and NK cells [29], mediate vascular
pericyte proliferation [25,26,30,31], act as powerful angio-
static agents [24–27] and, therefore, they are critically
involved in AR and CAN. Indeed, several studies demon-
strated increased expression of these chemokines in biop-
sies from subjects affected by AR or CAN [11,32,33].
Furthermore, neutralization of CXCL10 or CXL9 prolongs
the allograft survival [34–37].
However, targeting of a single chemokine is only par-
tially effective in promoting graft survival for long periods
of time [34–37], while treatment directed to block the
effects of all CXCR3-binding chemokines leads to perma-
nent engraftment in experimental animal models [26–
28,38].
Consistent with these studies, we have recently demon-
strated that measurement of pretransplant serum CXCL10
levels, but not of other unrelated chemokines, might rep-
resent the tracking of a clinically useful parameter to
identify subjects who are at higher risk for early, severe,
AR and subsequent chronic allograft nephropathy, finally
resulting in renal allograft failure [11,12]. These results
were confirmed by other studies [13,39], which suggested
that the measurement of the urinary levels of CXCL9, is
also useful to predict AR [13]. In this study we demon-
strate for the first time that higher pretransplant CXCL9
levels are associated with AR onset and severity, and of
bad graft outcome.
Recent reports have further investigated the role
played by CXCR3 and its ligand in organ transplant. In
detail, several experimental models of HLA-mismatched
mouse cardiac transplantation have shown a relatively lit-
tle prolongation of survival of full MHC-mismatched
allografts in CXCR3)/) recipients and no effects on cardiac
vasculopathy [40,41]. Moreover, the disruption or block-
ade of recipient CXCR3 had relatively little effects on
rejection of MHC-mismatched mouse cardiac allografts
[42,43]. These data leave many questions unanswered
about the role of CXCR3 and its ligands in allograft rejec-
tion, and also the question as to why CXCR3 ligands
CXCL9, CXCL10 and CXCL11 are so abundant. In this
regard, it is to be noted that CXCR3 ligands are not only
CXCR3 agonists but also are antagonists for other chemo-
kine receptors [44]; moreover, CXCR3 may act as a decoy
receptor [45]. Undoubtedly we need to develop a critical
view of the roles of ligand-receptor systems operating in
the inflammatory allograft, and our study attempts to
examine these processes during renal acute allograft rejec-
tion, even though in a small cohort of patients with differ-
ent HLA-mismatch(mean HLA-mismatch = 2.6).
In this study, we have also confirmed the predictive
role of CXCL10 in relation to graft outcome and have
assessed whether combined measurement of serum
CXCL9 and CXCL10 allows pretransplant estimation of
the risk for graft failure. Despite our results suggesting
that the measurement of both CXCL9 and CXCL10 might
indeed represent a more robust predictor of graft out-
come (Kaplan–Meier’s survival analysis and log-rank test
P < 0.001), no statistically significant differences have
been observed among the four different groups of
patients according to their pretransplant serum chemo-
kines status. This finding is probably resulting from the
too small number of patient analysed in our study and
this does not allow drawing firm conclusions. Thus, the
predictive role of the combined measurement of CXCL9
and CXCL10 in predicting graft outcome, as well as the
possible combined role of different targets (CXCL16,
CXCR6, FT3) in the perspective of a multi-parametric
evaluation of risk factor for graft loss, should be evaluated
in a larger number of patients.
In our cohort of patients, we observed a high incidence
of AR episodes, but this data may be explained by the
close selection criteria; in fact none of the patients that
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were included in this study received any induction ther-
apy. The main reason is that all the selected patients were
not hyper-immune time of transplantation (PRA < 20%).
Nevertheless few graft recipients, who had received an
induction therapy with basiliximab as participants of
Clinical Trials between 1991 and 2002, were excluded in
order to evaluate a homogeneous population with regard
to immunosuppressive therapy. In fact it is well known
that basiliximab reduces AR incidence in renal transplant
recipients when combined with the standard dual- or tri-
ple immunotherapy [46]. This choice, even if question-
able, has allowed us to rule out a confounding factor in
order to establish a possible correlation between high pre-
transplant levels of serum CXCL9 and onset of early AR
episodes.
Moreover, in this study, we have underlined the early
onset of AR because it is reasonable to infer that a pre-
transplant factor may affect the immune system during
an early period post-transplant, while after the first year,
the role of the post-transplant immunosuppressive regi-
men becomes prevalent.
The results of the kidney biopsy obtained from patients
affected by acute allograft rejection show high expression
of CXCL9 but do not permit drawing conclusion with
regards to the pathophysiologic mechanisms sustaining
the high levels of expression of the CXCR3-binding
chemokines during rejections. However, the elevated
expression of the CXCR3-binding chemokines in clinical
acute rejection samples and the results of studies in mur-
ine models of transplantation in which this chemokine
axis was genetically manipulated, would suggest that
CXCR3 and its ligands are involved in recruiting effector
T cells to the graft parenchyma [28,37,47–49]. Further-
more, a recent study demonstrated that CXCL9 from
both donor and recipient sources would act in synergy
during rejection of class II major histocompatibility com-
plex disparate skin allografts [50].
In conclusion, we show that the measurement of
CXCL9 serum levels before transplantation allows the
identification of highly reactive recipients with higher risk
of graft failure. Moreover, consistent with the well-estab-
lished involvement of CXCL9 in the immune response
towards the transplant, a higher pretransplant serum level
of CXCL9 characterized those patients experiencing AR in
the first post-transplant year.
A cut-off level (272.1 pg/ml) for CXCL9 was established,
which may be useful in clinical setting to identify candi-
dates for kidney transplantation with higher immunologic
risk. Although our findings should be confirmed by larger
randomized prospective studies, it seems reasonable to pro-
pose that measuring the pretransplant serum levels of
CXCL9 in patients undergoing renal transplantation may
be useful to estimate the acute allograft rejection risk, tailor
the peritransplant immunosuppressive regimens, with the
final aim of prolonging the long-term graft outcome.
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